Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre van Damme

Showing results (291-300 of 365) with videos related to

Pageof 37
Sort By:
Human Vaccines & Immunotherapeutics|March 3, 2026
A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adultsIlse De Coster, Isabel Leroux-Roels, Kanchanamala Withanage, et al.
Vaccine|November 16, 2010
Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)Germaine Hanquet, Pierre Van Damme, Daniel Brasseur, et al.
Vaccines|July 27, 2022
Electronic Package Leaflets for Vaccines: What Are People's Perceptions in Italy?Angela Bechini, Fabrizio Chiesi, Barbara Giammarco, et al.
Msphere|January 28, 2021
The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next GenerationManish Sadarangani, Tobias Kollmann, Gordean Bjornson, et al.
Journal of Medical Internet Research|August 11, 2021
Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods StudyTrésor Zola Matuvanga, Ginger Johnson, Ynke Larivière, et al.
Lancet (London, England)|March 19, 2023
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trialRoland Tschismarov, Pierre Van Damme, Clara Germain, et al.
The Journal of Infectious Diseases|February 6, 2018
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsJiri Beran, Jason D Lickliter, Tino F Schwarz, et al.
Journal of Viral Hepatitis|June 22, 2020
Stable HEV IgG seroprevalence in Belgium between 2006 and 2014Erwin Ho, Julie Schenk, Veronik Hutse, et al.
Vaccine|September 19, 2009
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adultsIsabel Leroux-Roels, Marie Van der Wielen, Froukje Kafeja, et al.
Plos One|October 8, 2011
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adultsPierre van Damme, Froukje Kafeja, Alessandra Anemona, et al.
Pageof 37

Showing results (291-300 of 365) with videos related to

Sort By:
Pageof 37
Human Vaccines & Immunotherapeutics|March 3, 2026
A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adultsIlse De Coster, Isabel Leroux-Roels, Kanchanamala Withanage, et al.
Vaccine|November 16, 2010
Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010)Germaine Hanquet, Pierre Van Damme, Daniel Brasseur, et al.
Vaccines|July 27, 2022
Electronic Package Leaflets for Vaccines: What Are People's Perceptions in Italy?Angela Bechini, Fabrizio Chiesi, Barbara Giammarco, et al.
Msphere|January 28, 2021
The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next GenerationManish Sadarangani, Tobias Kollmann, Gordean Bjornson, et al.
Journal of Medical Internet Research|August 11, 2021
Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods StudyTrésor Zola Matuvanga, Ginger Johnson, Ynke Larivière, et al.
Lancet (London, England)|March 19, 2023
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trialRoland Tschismarov, Pierre Van Damme, Clara Germain, et al.
The Journal of Infectious Diseases|February 6, 2018
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsJiri Beran, Jason D Lickliter, Tino F Schwarz, et al.
Journal of Viral Hepatitis|June 22, 2020
Stable HEV IgG seroprevalence in Belgium between 2006 and 2014Erwin Ho, Julie Schenk, Veronik Hutse, et al.
Vaccine|September 19, 2009
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adultsIsabel Leroux-Roels, Marie Van der Wielen, Froukje Kafeja, et al.
Plos One|October 8, 2011
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adultsPierre van Damme, Froukje Kafeja, Alessandra Anemona, et al.
Pageof 37